Passage Bio Inc reports results for the quarter ended June 30 - Earnings Summary

• Passage Bio Inc PASG.OQ reported a quarterly adjusted loss of $2.96​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.20. The mean expectation of four analysts for the quarter was for a loss of $4.05 per share. Wall Street expected results to range from $-5.00 to $-3.20 per share.

• Reported revenue was zero​; analysts expected zero.

• Passage Bio Inc's reported EPS for the quarter was a loss of $2.96​.

• The company reported a quarterly loss of $9.39 million.

• Passage Bio Inc shares had fallen by 26.3% this quarter and lost 48.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 3.6% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Passage Bio Inc is $120.00, about 95.1% above its last closing price of $5.90

This summary was machine generated from LSEG data August 12 at 11:49 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)